ECCO 2020

Gut Microbiome as Treatment Target

Response to faecal microbiota transplantation in UC

Presented By

Dr M. Quraishi, University Hospital Birmingham, UK; Dr L. Gogokhia, Weill Cornell Medicine, New York, USA

Trial

STOP-Colitis

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 10:55

Impact of biologicals on faecal microbiota

Presented By

C. Caenepeel, KU Leuven, Belgium

Conference

ECCO 2020

14 April 2020 10:20

Bioactives produced by gut bacteria to modulate immune response

Presented By

R. Giri, University of Queensland, Australia

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 10:13

Big Data Analysis

Experimental Therapies: Study Results

Short- and Long-Term Treatment Results

Infliximab discontinuation increases relapse risk

Presented By

Kobayashi T, Kitasato University, Japan

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:41

Tofacitinib ‘real-world’ effectiveness in active UC

Presented By

Dr M. Chaparro , Hospital Universitario de La Princesa, Spain

Trial

OCTAVE

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:39

Ustekinumab in CD: a T2T trial

Presented By

Prof. L. Peyrin-Biroulet, CHRU de Nancy, France

Trial

Phase 3, STARDUST

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:26

Subcutaneous ustekinumab as maintenance therapy in UC

Presented By

Dr R. Panaccione & Dr W.J. Sandborn

Trial

UNIFI

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:22

Subcutaneous vedolizumab maintenance therapy in CD

Presented By

Prof. S. Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, VISIBLE 2

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:11

Vedolizumab treatment persistence and safety

Presented By

Dr S. Danese & Dr N.A. Cohen, Humanitas University, Milan, Italy

Trial

GEMINI

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:04

Specific Therapeutic Strategies

On the cutting edge of pathology and surgery

Presented By

Prof. P. B. Nunes & Prof. A. Spinelli

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:23

Impact of strategies on intestinal resection rate

Presented By

Dr D. Ley, University of Wisconsin–Madison, USA

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:16

Early ileocaecal resection in CD patients failing conventional treatment

Presented By

Dr T. Stevens, Amsterdam UMC, the Netherlands

Trial

LIR!C

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:11

Biologics before surgery in IBD do not elevate infection risk

Presented By

Dr S. Holubar, Cleveland Clinic, USA

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:06

Top-down infliximab superior to step-up in children with CD

Presented By

Dr M. Jongsma, Erasmus MC, the Netherlands

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:59

High versus standard adalimumab in active UC

Presented By

Prof. J. Colombel, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 3, SERENE-UC

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:47

Head-to-Head Comparison of Treatments

Effects of vedolizumab versus adalimumab on QoL

Presented By

Dr E.V. Loftus, Mayo Clinic, USA

Trial

VARSITY

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:39

Vedolizumab and anti-TNF therapies: a real-world comparison

Presented By

Dr G. Mantzaris , Evangelismos Hospital, Greece

Trial

EVOLVE

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:35

Vedolizumab, adalimumab, and golimumab compared

Presented By

Dr F.S. Macaluso & Dr A. Casanotti

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:32

Vedolizumab versus ustekinumab

Presented By

Dr H. Alric & Dr V. Biemans

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:28

Cancer Risk

Miscellaneous Topics